MUC3A基因在神经母细胞瘤中的甲基化状态及其与预后的关系  

Status of MUC3A Methylation in NB and Its Relationship with Prognosis

作　　者：吴迪[1] 张可仞[1] 

机构地区：[1]中国医科大学附属盛京医院小儿普通外科,沈阳市110004

出　　处：《中国肿瘤临床》2012年第15期1020-1024,共5页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨神经母细胞瘤中MUC3A基因甲基化状态与肿瘤预后的关系。方法:收集2009年3月至2011年5月中国医科大学附属盛京医院小儿外科收治神经母细胞瘤新鲜冰冻原发肿瘤组织44例,采用RT-PCR法检测44例肿瘤组织标本中MYCN基因扩增状态,MSP检测肿瘤组织MUC3A甲基化状态。结果:NB中MUC3A基因甲基化发生率达79.55%(35/44),且与患儿年龄、肿瘤分期及病理分型密切相关(P<0.05),低危组甲基化发生率38.46%明显低于中危组100%及高危组92.31%(P<0.05);MYCN扩增的肿瘤患者MUC3A基因的甲基化发生率明显升高(RR=1.46,P<0.005)。结论:预后不良的NB中MUC3A基因呈高甲基化,与MYCN基因扩增具有相关性,该基因的表达对NB的预后评估具有重要临床意义,是预后不良的主要因素之一。Objective： The present study explores MUC3A methylation and evaluates its effects on the prognosis of neuroblastoma （ NB ）. Methods： Fresh frozen primary tumor tissue sections from 44 NB patients were collected consecutively from March 2009 to May 2011. We detected the status of N-MYC amplification and MUC3A methylation in the 44 NB patients by RT-PCR and MSP. Results： MUC3A is methylated by 79.55% （35/44）, and the DNA methylation pattern is intimately correlated with age, INSS stage, and pathology type （ P 〈 0.05 ） in NB. Methylation in the low-risk group （ 38.46% ） was significantly less than that in the intermediate-risk group （ 100% ） and high-risk group （ 92.31% ）. As expected, the risk of methylation was higher in the MYCN-amplified patients （ RR = 1.46, P 〈 0.005 ）. Conclusion： Methylation in the poor prognosis NB of MUC3A is high. Based on its correlation with MYCN gene amplification, methylation of MUC3A, as a factor of poor prognosis, has clinical significance in the prognostic evaluation of NB.

关 键 词：神经母细胞瘤 MUC3A 甲基化 

分 类 号：R739.4[医药卫生—肿瘤]